![](/img/cover-not-exists.png)
Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data
Sattar, Naveed, Preiss, David, Robinson, Jennifer G, Djedjos, C Stephen, Elliott, Mary, Somaratne, Ransi, Wasserman, Scott M, Raal, Frederick JLanguage:
english
Journal:
The Lancet Diabetes & Endocrinology
DOI:
10.1016/S2213-8587(16)00003-6
Date:
February, 2016
File:
PDF, 484 KB
english, 2016